National Bank of Canada FI Buys 128,843 Shares of IQVIA Holdings Inc. (NYSE:IQV)

National Bank of Canada FI lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 245.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 181,423 shares of the medical research company's stock after purchasing an additional 128,843 shares during the quarter. National Bank of Canada FI owned about 0.10% of IQVIA worth $42,992,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. First Foundation Advisors raised its holdings in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock worth $245,000 after acquiring an additional 43 shares in the last quarter. Invera Wealth Advisors LLC lifted its position in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock valued at $3,183,000 after purchasing an additional 46 shares during the last quarter. Private Trust Co. NA grew its stake in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after buying an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock worth $3,313,000 after buying an additional 48 shares during the last quarter. Finally, Continuum Advisory LLC raised its position in shares of IQVIA by 3.3% during the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock valued at $325,000 after buying an additional 49 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. Evercore ISI decreased their price target on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Leerink Partners reaffirmed an "outperform" rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, Truist Financial dropped their price target on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Stock Up 1.9 %

Shares of IQV stock traded up $3.94 on Monday, hitting $206.57. The stock had a trading volume of 1,748,952 shares, compared to its average volume of 1,182,643. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business has a 50 day moving average price of $214.57 and a 200 day moving average price of $224.96. The company has a market cap of $37.49 billion, a PE ratio of 27.11, a P/E/G ratio of 2.08 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.